357 related articles for article (PubMed ID: 24136036)
1. Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes.
Bosch X; Marrugat J; Sanchis J
Cochrane Database Syst Rev; 2013 Oct; (10):CD002130. PubMed ID: 24136036
[TBL] [Abstract][Full Text] [Related]
2. Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes.
Bosch X; Marrugat J; Sanchis J
Cochrane Database Syst Rev; 2013 Nov; (11):CD002130. PubMed ID: 24203004
[TBL] [Abstract][Full Text] [Related]
3. Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes.
Bosch X; Marrugat J; Sanchis J
Cochrane Database Syst Rev; 2010 Sep; (9):CD002130. PubMed ID: 20824831
[TBL] [Abstract][Full Text] [Related]
4. Platelet glycoprotein IIb/IIIa blockers for percutaneous coronary revascularization, and unstable angina and non-ST-segment elevation myocardial infarction.
Bosch X; Marrugat J
Cochrane Database Syst Rev; 2001; (4):CD002130. PubMed ID: 11687143
[TBL] [Abstract][Full Text] [Related]
5. Upstream use of small-molecule glycoprotein iib/iiia inhibitors in patients with non-ST-segment elevation acute coronary syndromes: a systematic overview of randomized clinical trials.
Tricoci P; Newby LK; Hasselblad V; Kong DF; Giugliano RP; White HD; Théroux P; Stone GW; Moliterno DJ; Van de Werf F; Armstrong PW; Prabhakaran D; Rasoul S; Bolognese L; Durand E; Braunwald E; Califf RM; Harrington RA
Circ Cardiovasc Qual Outcomes; 2011 Jul; 4(4):448-58. PubMed ID: 21712522
[TBL] [Abstract][Full Text] [Related]
6. Bivalirudin versus heparin plus a glycoprotein IIb/IIIa inhibitor in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention after clopidogrel pretreatment: pooled analysis from the ACUITY and ISAR-REACT 4 trials.
Ndrepepa G; Neumann FJ; Deliargyris EN; Mehran R; Mehilli J; Ferenc M; Schulz S; Schömig A; Kastrati A; Stone GW
Circ Cardiovasc Interv; 2012 Oct; 5(5):705-12. PubMed ID: 23048052
[TBL] [Abstract][Full Text] [Related]
7. What anti-thrombotic therapy is best with primary PCI for acute ST elevation myocardial infarction: how should the HORIZONS trial change current practice?
Brodie BR
Catheter Cardiovasc Interv; 2008 May; 71(6):816-21. PubMed ID: 18412079
[TBL] [Abstract][Full Text] [Related]
8. Influence of timing of clopidogrel treatment on the efficacy and safety of bivalirudin in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention: an analysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.
Lincoff AM; Steinhubl SR; Manoukian SV; Chew D; Pollack CV; Feit F; Ware JH; Bertrand ME; Ohman EM; Desmet W; Cox DA; Mehran R; Stone GW;
JACC Cardiovasc Interv; 2008 Dec; 1(6):639-48. PubMed ID: 19463378
[TBL] [Abstract][Full Text] [Related]
9. Effects of glycoprotein IIb/IIIa inhibitors in patients undergoing percutaneous coronary intervention after pretreatment with clopidogrel: a meta-analysis of randomized trials.
Pannu R; Andraws R
Crit Pathw Cardiol; 2008 Mar; 7(1):5-10. PubMed ID: 18458661
[TBL] [Abstract][Full Text] [Related]
10. Meta-analysis of randomized clinical trials comparing bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in patients undergoing percutaneous coronary intervention and in patients with ST-segment elevation myocardial infarction.
Nairooz R; Sardar P; Amin H; Swaminathan RV; Kim LK; Chatterjee S; Feldman DN
Am J Cardiol; 2014 Jul; 114(2):250-9. PubMed ID: 24890986
[TBL] [Abstract][Full Text] [Related]
11. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials.
Boersma E; Harrington RA; Moliterno DJ; White H; Théroux P; Van de Werf F; de Torbal A; Armstrong PW; Wallentin LC; Wilcox RG; Simes J; Califf RM; Topol EJ; Simoons ML
Lancet; 2002 Jan; 359(9302):189-98. PubMed ID: 11812552
[TBL] [Abstract][Full Text] [Related]
12. Platelet inhibitors in non-ST-segment elevation acute coronary syndromes and percutaneous coronary intervention: glycoprotein IIb/IIIa inhibitors, clopidogrel, or both?
Silva MA; Donovan JL; Gandhi PJ; Volturo GA
Vasc Health Risk Manag; 2006; 2(1):39-48. PubMed ID: 17319468
[TBL] [Abstract][Full Text] [Related]
13. Meta-analysis of clinical efficacy and bleeding risk with intravenous glycoprotein IIb/IIIa antagonists for percutaneous coronary intervention.
Labinaz M; Ho C; Banerjee S; Martin J; Chen S; Mensinkai S
Can J Cardiol; 2007 Oct; 23(12):963-70. PubMed ID: 17932572
[TBL] [Abstract][Full Text] [Related]
14. Lack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin with provisional glycoprotein IIb/IIIa blockade compared to heparin with routine glycoprotein IIb/IIIa blockade: a REPLACE-2 substudy.
Saw J; Lincoff AM; DeSmet W; Betriu A; Rutsch W; Wilcox RG; Kleiman NS; Wolski K; Topol EJ;
J Am Coll Cardiol; 2004 Sep; 44(6):1194-9. PubMed ID: 15364319
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness and safety of glycoprotein IIb/IIIa inhibitors and clopidogrel alone and in combination in non-ST-segment elevation myocardial infarction (from the National Registry of Myocardial Infarction-4).
Bromberg-Marin G; Marin-Neto JA; Parsons LS; Canto JG; Rogers WJ;
Am J Cardiol; 2006 Nov; 98(9):1125-31. PubMed ID: 17056312
[TBL] [Abstract][Full Text] [Related]
16. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial.
Lincoff AM; Bittl JA; Harrington RA; Feit F; Kleiman NS; Jackman JD; Sarembock IJ; Cohen DJ; Spriggs D; Ebrahimi R; Keren G; Carr J; Cohen EA; Betriu A; Desmet W; Kereiakes DJ; Rutsch W; Wilcox RG; de Feyter PJ; Vahanian A; Topol EJ;
JAMA; 2003 Feb; 289(7):853-63. PubMed ID: 12588269
[TBL] [Abstract][Full Text] [Related]
17. Frequency and outcomes of provisional glycoprotein IIb/IIIa blockade in patients receiving bivalirudin during percutaneous coronary intervention.
Feldman DN; Wong SC; Bergman G; Minutello RM
J Invasive Cardiol; 2009 Jun; 21(6):258-63. PubMed ID: 19494400
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial.
Blazing MA; de Lemos JA; White HD; Fox KA; Verheugt FW; Ardissino D; DiBattiste PM; Palmisano J; Bilheimer DW; Snapinn SM; Ramsey KE; Gardner LH; Hasselblad V; Pfeffer MA; Lewis EF; Braunwald E; Califf RM;
JAMA; 2004 Jul; 292(1):55-64. PubMed ID: 15238591
[TBL] [Abstract][Full Text] [Related]
19. Routine invasive strategies versus selective invasive strategies for unstable angina and non-ST elevation myocardial infarction in the stent era.
Fanning JP; Nyong J; Scott IA; Aroney CN; Walters DL
Cochrane Database Syst Rev; 2016 May; 2016(5):CD004815. PubMed ID: 27226069
[TBL] [Abstract][Full Text] [Related]
20. Early vs late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction: a meta-analysis.
Montalescot G; Borentain M; Payot L; Collet JP; Thomas D
JAMA; 2004 Jul; 292(3):362-6. PubMed ID: 15265852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]